Everything tagged "healthcare" across the TickerSpark archives.
Medical Properties Trust shows a credible stabilization story as rent ramps and restructurings improve, but heavy leverage and tenant risk keep the stock in Hold territory.
Sonida Senior Living, Inc. (SNDA) slips 1.5% after reporting earnings misses, with investors reacting to weaker-than-expected results and renewed pressure on the stock.
TEM's 13% surge is running ahead of an unprofitable business and a $1.5 billion Personalis deal that adds scale before it adds clean earnings. Strong revenue growth is real, but dilution, cash needs, and insider selling make this rally one to fade rather than chase.
Sonida Senior Living is showing real operating momentum, with higher occupancy and margin expansion after its CHP acquisition. But a $1.6B debt load and ongoing losses keep this a cautious Hold.
Insmed is transitioning from cash-burning biotech to a commercial respiratory growth story, powered by BRINSUPRI’s rapid launch and improving margins. The stock looks attractive on execution, but valuation already reflects meaningful success.
Elanco is showing real momentum from Zenrelia and Credelio Quattro, with 2026 guidance rising and organic growth improving across pet and farm animal lines. The stock still carries meaningful balance-sheet risk, so the upside case depends on execution and debt reduction.
ResMed pairs double-digit revenue growth, strong margins, and net cash with a large underpenetrated sleep-apnea market. The stock remains a Buy, but valuation and an Astral field-action headwind temper upside.
Boston Scientific posted solid Q2 2026 growth, but lowered full-year guidance as WATCHMAN and U.S. EP slowed. The stock looks more reasonable after the reset, with durable pipeline optionality and a Buy rating.
Natera posted 39% Q1 revenue growth and continued rapid oncology and women’s health expansion, but losses and a rich valuation keep the stock at Hold. The report sees strong long-term clinical momentum, yet limited margin of safety at the current price.
Kenvue is showing early stabilization with improving margins and revenue growth, but debt, mixed segment performance, and a pending Kimberly-Clark combination keep the stock in Hold territory.
Zoetis remains a Buy for investors willing to wait for a premium pet-care rebound. Strong margins, cash flow, and a deep pipeline are offset by softer U.S. companion-animal trends and elevated leverage.
BeOne Medicines is delivering strong oncology growth, led by BRUKINSA and expanding TEVIMBRA sales. The stock earns a Buy, but a premium valuation and product concentration keep the risk profile elevated.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime